Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2010
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 94 citations in OpenAlex.
- A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.Leukemia research · 2021Trial
- S-1 plus CIK as second-line treatment for advanced pancreatic cancer.Medical oncology (Northwood, London, England) · 2013Trial
- Review
- Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells.Cellular and molecular life sciences : CMLS · 2024Review
- A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors.Cancer research communications · 2024Article
- Electrically regulated cell-based intervention for viral infections.Bioengineering & translational medicine · 2023Article
- Changing Landscape of Cancer Vaccines-Novel Proteomics Platform for New Antigen Compositions.International journal of molecular sciences · 2022Article
- Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation.Frontiers in oncology · 2022Article
- A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.Emerging microbes & infections · 2021Article
- [Tumor vaccination-strategies and time points].Der Internist · 2021Review
- Myelodysplastic syndrome and immunotherapy novel to next in-line treatments.Human vaccines & immunotherapeutics · 2021Review
- Biomaterial-based platforms for in situ dendritic cell programming and their use in antitumor immunotherapy.Journal for immunotherapy of cancer · 2019Review
- Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells.Frontiers in immunology · 2019Article
- HLA-Class II Artificial Antigen Presenting Cells in CD4Frontiers in immunology · 2019Review
- Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients.Leukemia & lymphoma · 2018Article
- Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil.Journal of translational medicine · 2018Article
- Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.Molecular cancer · 2018Review
- Gene and virotherapy for hematological malignancies.International journal of hematology · 2016Review
- Current status of ex vivo gene therapy for hematological disorders: a review of clinical trials in Japan around the world.International journal of hematology · 2016Review
- Adjuvants for peptide-based cancer vaccines.Journal for immunotherapy of cancer · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
Abstract
purposeChronic myeloid leukemia (CML) can be responsive to T-cell-mediated immunity. K562/granulocyte macrophage-colony stimulating factor (GM-CSF) is a GM-CSF producing vaccine derived from a CML cell line that expresses several CML-associated antigens. A pilot study was developed to determine if K562/GM-CSF immunotherapy could improve clinical responses to imatinib mesylate (IM) in patients with chronic myeloid leukemia. EXPERIMENTAL
designPatients with chronic phase CML who achieved at least a major cytogeneic response but remained with persistent, measurable disease despite one or more years on imatinib mesylate were eligible. Each was given a series of four vaccines administered in three-week intervals, with or without topical imiquimod, while remaining on a stable dose of imatinib mesylate. CML disease burden was measured serially before and after vaccination.
resultsNineteen patients were vaccinated, with a median duration of previous imatinib mesylate therapy of 37 (13-53) months. Mean PCR measurements of BCR-ABL for the group declined significantly following the vaccines (P = 0.03). Thirteen patients had a progressive decline in disease burden, 8 of whom had increasing disease burden before vaccination. Twelve patients achieved their lowest tumor burden measurements to date following vaccine, including seven subjects who became PCR-undetectable.
conclusionsK562/GM-CSF vaccine appears to improve molecular responses in patients on imatinib mesylate, including achieving complete molecular remissions, despite long durations of previous imatinib mesylate therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.